Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.
Lefferdink R, Rangel SM, Chima M, Ibler E, Pavel AB, Kim H, Wu B, Abu-Zayed H, Wu J, Jackson K, Singer G, Choate KA, Guttman-Yassky E, Paller AS. Lefferdink R, et al. Among authors: singer g. Arch Dermatol Res. 2023 Mar;315(2):305-315. doi: 10.1007/s00403-022-02325-3. Epub 2022 Feb 26. Arch Dermatol Res. 2023. PMID: 35218370 Free PMC article. Clinical Trial.
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D, Glickman JW, Del Duca E, Nia J, Hashim P, Singer GK, Posligua AL, Florek AG, Ibler E, Hagstrom EL, Estrada Y, Rangel SM, Colavincenzo M, Paller AS, Guttman-Yassky E. Mikhaylov D, et al. Among authors: singer gk. Arch Dermatol Res. 2023 Mar;315(2):181-189. doi: 10.1007/s00403-022-02336-0. Epub 2022 Mar 1. Arch Dermatol Res. 2023. PMID: 35230488 Clinical Trial.
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI.
Kim HJ, Del Duca E, Pavel AB, Singer GK, Abittan BJ, Chima MA, Kimmel G, Bares J, Baum D, Gagliotti M, Genece J, Chu J, Lebwohl MG, Guttman-Yassky E. Kim HJ, et al. Among authors: singer gk. Arch Dermatol Res. 2023 Mar;315(2):215-221. doi: 10.1007/s00403-022-02343-1. Epub 2022 Mar 13. Arch Dermatol Res. 2023. PMID: 35279741 Clinical Trial.
A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D, Pavel A, Yao C, Kimmel G, Nia J, Hashim P, Vekaria AS, Taliercio M, Singer G, Karalekas R, Baum D, Mansouri Y, Lebwohl MG, Guttman-Yassky E. Mikhaylov D, et al. Among authors: singer g. Arch Dermatol Res. 2019 Jan;311(1):29-36. doi: 10.1007/s00403-018-1876-y. Epub 2018 Nov 11. Arch Dermatol Res. 2019. PMID: 30417279 Clinical Trial.
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.
Ungar B, Pavel AB, Li R, Kimmel G, Nia J, Hashim P, Kim HJ, Chima M, Vekaria AS, Estrada Y, Xu H, Peng X, Singer GK, Baum D, Mansouri Y, Taliercio M, Guttman-Yassky E. Ungar B, et al. Among authors: singer gk. J Allergy Clin Immunol. 2021 Jan;147(1):394-397. doi: 10.1016/j.jaci.2020.04.055. Epub 2020 May 16. J Allergy Clin Immunol. 2021. PMID: 32428528 Clinical Trial. No abstract available.
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, Sullivan-Whalen M, Singer GK, Garcet S, Pavel AB, Lebwohl MG, Krueger JG. Guttman-Yassky E, et al. Among authors: singer gk. Allergy. 2022 Mar;77(3):897-906. doi: 10.1111/all.15071. Epub 2021 Sep 6. Allergy. 2022. PMID: 34460948 Free PMC article. Clinical Trial.
Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation.
Glickman JW, Dubin C, Renert-Yuval Y, Dahabreh D, Kimmel GW, Auyeung K, Estrada YD, Singer G, Krueger JG, Pavel AB, Guttman-Yassky E. Glickman JW, et al. Among authors: singer g. J Am Acad Dermatol. 2021 Feb;84(2):370-380. doi: 10.1016/j.jaad.2020.04.138. Epub 2020 May 4. J Am Acad Dermatol. 2021. PMID: 32376430
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.
Ungar B, Glickman JW, Golant AK, Dubin C, Marushchak O, Gontzes A, Mikhaylov D, Singer GK, Baum D, Wei N, Sanin A, Gruenstein D, Lebwohl MG, Pavel AB, Guttman-Yassky E. Ungar B, et al. Among authors: singer gk. J Allergy Clin Immunol Pract. 2022 Jan;10(1):134-142. doi: 10.1016/j.jaip.2021.10.050. Epub 2021 Nov 1. J Allergy Clin Immunol Pract. 2022. PMID: 34737108 Free PMC article.
The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis.
Ungar B, Lavin L, Golant AK, Gontzes A, David E, Estrada YD, Singer GK, Pavel AB, Guttman-Yassky E. Ungar B, et al. Ann Allergy Asthma Immunol. 2022 Jun;128(6):734-736. doi: 10.1016/j.anai.2022.03.019. Epub 2022 Mar 26. Ann Allergy Asthma Immunol. 2022. PMID: 35346880 Free PMC article. No abstract available.
662 results